Tarr Mark J

CEO Mark J Tarr sells 150,000 shares at $111.64 avg for $16.7M on 2026-02-11 (-28.5% of holdings)

Mark J Tarr, President & CEO of Encompass Health Corp, executed 7 separate sales totaling 150,000 shares (150.0K shares) for $16,746,688.16 ($16.7M) on 2026-02-11, reducing his holdings by 28.5% to 377.1K shares. The blended average sale price of $111.64 sits 0.4% above the current price of $112.06 and -11.9% below the 52-week high of $127.18, indicating sales executed near recent highs but ahead of a 12-month pullback. His cross-ticker track record shows a 75.00% well-timed rate on 4 prior sells with an average 90-day return of -0.2%, and at EHC specifically, 3 of 4 prior sells occurred before or during downward periods (90-day returns of -1.0%, -1.5%, and -9.0% on three of those trades). The company's fundamentals remain solid with FY revenue growth of +11.9%, P/E of 20.83, and $1.5B quarterly revenue, though the magnitude of this sale—the largest proportion of holdings liquidated by this executive in recent filings—warrants close observation of market sentiment and third-quarter guidance.

EHC CEO Mark Tarr sells 118,384 shares for $14,387,152.06; holdings drop 18.3% post-transaction

Mark Tarr, President & CEO of Encompass Health Corp, executed two separate sales on 2025-05-20 totaling 118,384 shares (118.4K shares) for $14,387,152.06 ($14.4M) at a blended average price of $121.53, reducing his post-transaction holdings to 527,070 shares (527.1K shares) from 645,454 shares (645.5K shares)—a net reduction of 18.3% of pre-transaction holdings. The sale occurred at the 52-week high price of $121.73 (current price), with the stock up 17.8% over the prior 30 days and 19.8% over the prior 90 days, following recent strong momentum. Examining Tarr's cross-ticker track record, his 2 prior open-market sells averaged -0.8% 30-day return and +0.4% 90-day return with a 50.00% well-timed rate, indicating his sell timing has been mixed historically; at EHC specifically, his prior 2 sales showed divergent timing outcomes (2024 sale: +2.8% / +9.9% at 30/90 days; 2023 sale: -4.4% / -9.0% at 30/90 days). The company's fundamentals remain solid with $1.5B in latest quarterly revenue, $151.5M net income, 11.9% annual revenue growth, and a P/E of 24.79, with a market cap of $12.3B. The significance of this trade lies in the substantial dollar value and the percentage of holdings divested during a period of elevated stock momentum, warranting investor attention to the magnitude and timing context.